skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

Abstract

Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether early response kinetics can provide the basis to individualize therapy to achieve optimal results while reducing duration and cost. 58 chronic HCV patients were treated with 12-week sofosbuvir + simeprevir (n = 19), sofosbuvir + daclatasvir (n = 19), or sofosbuvir + ledipasvir in three French referral centers. HCV was measured at baseline, day 2, every other week, EOT and 12 weeks post EOT. Furthermore, mathematical modeling was used to predict the time to cure, i.e., <1 virus copy in the entire extracellular body fluid. All but one patient who relapsed achieved SVR. Mean age was 60 ± 11 years, 53% were male, 86% HCV genotype-1, 9% HIV coinfected, 43% advanced fibrosis (F3), and 57% had cirrhosis. At weeks 2, 4 and 6, 48%, 88% and 100% of patients had HCV <15 IU/ml, with 27%, 74% and 91% of observations having target not detected, respectively. Modeling results predicted that 23 (43%), 16 (30%), 7 (13%), 5 (9%) and 3 (5%) subjects were predictedmore » to reach cure within 6, 8, 10, 12 and 13 weeks of therapy, respectively. The modeling suggested that the patient who relapsed would have benefitted from an additional week of sofosbuvir + ledipasvir. Adjusting duration of treatment according to the modeling predicts reduced medication costs of 43–45% and 17–30% in subjects who had HCV <15 IU/ml at weeks 2 and 4, respectively. Finally, the use of early viral kinetic analysis has the potential to individualize duration of DAA therapy with a projected average cost saving of 16–20% per 100-treated persons.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [7];  [7];  [8];  [9];  [8];  [4];  [10]
  1. Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling; Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics Group
  2. Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling; Univ. of Edinburgh, Scotland (United Kingdom). Center for Immunity
  3. Heidelberg Univ. (Germany). Cetner for Modeling and Simulation in the Biosciences
  4. Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling
  5. Univ. of Sao Paulo Hospital das Cinicas (Brazil)
  6. Alphabio Lab., Marseille (France)
  7. European Hospital, Marseille (France). Internal Medicine and Infectious Disease
  8. Saint Joseph Hospital, Marseille (France). Division of Hepatology
  9. CH Hyeres (France). Division of Hepatology
  10. Alphabio Lab., Marseille (France); European Hospital, Marseille (France). Internal Medicine and Infectious Disease
Publication Date:
Research Org.:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
USDOE; National Institutes of Health (NIH)
OSTI Identifier:
1334130
Alternate Identifier(s):
OSTI ID: 1467524
Report Number(s):
LA-UR-15-27222
Journal ID: ISSN 0168-8278
Grant/Contract Number:  
AC52-06NA25396; 1698:BB/L001330/1
Resource Type:
Accepted Manuscript
Journal Name:
Journal of Hepatology
Additional Journal Information:
Journal Volume: 64; Journal Issue: 6; Journal ID: ISSN 0168-8278
Publisher:
Elsevier
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; Biological Science

Citation Formats

Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S. A., Penaranda, Guillaume, Coquet, Emilie, Chiche, Laurent, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., and Halfon, Philippe. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. United States: N. p., 2016. Web. https://doi.org/10.1016/j.jhep.2016.02.022.
Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S. A., Penaranda, Guillaume, Coquet, Emilie, Chiche, Laurent, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., & Halfon, Philippe. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. United States. https://doi.org/10.1016/j.jhep.2016.02.022
Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S. A., Penaranda, Guillaume, Coquet, Emilie, Chiche, Laurent, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., and Halfon, Philippe. Wed . "HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir". United States. https://doi.org/10.1016/j.jhep.2016.02.022. https://www.osti.gov/servlets/purl/1334130.
@article{osti_1334130,
title = {HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir},
author = {Dahari, Harel and Canini, Laetitia and Graw, Frederik and Uprichard, Susan L. and Araújo, Evaldo S. A. and Penaranda, Guillaume and Coquet, Emilie and Chiche, Laurent and Riso, Aurelie and Renou, Christophe and Bourliere, Marc and Cotler, Scott J. and Halfon, Philippe},
abstractNote = {Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether early response kinetics can provide the basis to individualize therapy to achieve optimal results while reducing duration and cost. 58 chronic HCV patients were treated with 12-week sofosbuvir + simeprevir (n = 19), sofosbuvir + daclatasvir (n = 19), or sofosbuvir + ledipasvir in three French referral centers. HCV was measured at baseline, day 2, every other week, EOT and 12 weeks post EOT. Furthermore, mathematical modeling was used to predict the time to cure, i.e., <1 virus copy in the entire extracellular body fluid. All but one patient who relapsed achieved SVR. Mean age was 60 ± 11 years, 53% were male, 86% HCV genotype-1, 9% HIV coinfected, 43% advanced fibrosis (F3), and 57% had cirrhosis. At weeks 2, 4 and 6, 48%, 88% and 100% of patients had HCV <15 IU/ml, with 27%, 74% and 91% of observations having target not detected, respectively. Modeling results predicted that 23 (43%), 16 (30%), 7 (13%), 5 (9%) and 3 (5%) subjects were predicted to reach cure within 6, 8, 10, 12 and 13 weeks of therapy, respectively. The modeling suggested that the patient who relapsed would have benefitted from an additional week of sofosbuvir + ledipasvir. Adjusting duration of treatment according to the modeling predicts reduced medication costs of 43–45% and 17–30% in subjects who had HCV <15 IU/ml at weeks 2 and 4, respectively. Finally, the use of early viral kinetic analysis has the potential to individualize duration of DAA therapy with a projected average cost saving of 16–20% per 100-treated persons.},
doi = {10.1016/j.jhep.2016.02.022},
journal = {Journal of Hepatology},
number = 6,
volume = 64,
place = {United States},
year = {2016},
month = {6}
}

Journal Article:

Citation Metrics:
Cited by: 15 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Hepatitis C
journal, March 2015


HCV direct-acting antiviral agents: the best interferon-free combinations
journal, December 2013

  • Schinazi, Raymond; Halfon, Philippe; Marcellin, Patrick
  • Liver International, Vol. 34
  • DOI: 10.1111/liv.12423

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
journal, July 2014


From non-A, non-B hepatitis to hepatitis C virus cure
journal, April 2015


The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus
journal, March 2015

  • Rein, David B.; Wittenborn, John S.; Smith, Bryce D.
  • Clinical Infectious Diseases, Vol. 61, Issue 2
  • DOI: 10.1093/cid/civ220

Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
journal, August 2008


Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection
journal, April 2009

  • Hoofnagle, Jay H.; Wahed, Abdus S.; Brown, Jr., Robert S.
  • The Journal of Infectious Diseases, Vol. 199, Issue 8
  • DOI: 10.1086/597384

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients
journal, June 2014


Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics
journal, October 2014

  • Dahari, Harel; Shteingart, Shimon; Gafanovich, Inna
  • Liver International, Vol. 35, Issue 2
  • DOI: 10.1111/liv.12692

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
journal, February 2005


FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy
journal, November 2007

  • Shaheen, Abdel Aziz M.; Wan, Alex F.; Myers, Robert P.
  • The American Journal of Gastroenterology, Vol. 102, Issue 11, p. 2589-2600
  • DOI: 10.1111/j.1572-0241.2007.01466.x

Utilization of FibroScan in Clinical Practice
journal, January 2014


Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study
journal, January 2012


Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998


Maximum likelihood estimation in nonlinear mixed effects models
journal, June 2005


A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010

  • Snoeck, E.; Chanu, P.; Lavielle, M.
  • Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
  • DOI: 10.1038/clpt.2010.35

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004

  • Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
  • Nature, Vol. 432, Issue 7019
  • DOI: 10.1038/nature03153

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
journal, May 2014

  • Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender
  • New England Journal of Medicine, Vol. 370, Issue 20
  • DOI: 10.1056/NEJMoa1402355

P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial
journal, April 2015


Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
journal, March 2015


Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy
journal, March 2015


Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials: Table 1.
journal, May 2015

  • Harrington, Patrick R.; Deming, Damon J.; Komatsu, Takashi E.
  • Clinical Infectious Diseases, Vol. 61, Issue 4
  • DOI: 10.1093/cid/civ402

Effect of IL28B genotype on hepatitis B and C virus infection
journal, October 2015


Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
journal, March 2013


Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013

  • Guedj, J.; Dahari, H.; Rong, L.
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
  • DOI: 10.1073/pnas.1203110110

Individualized treatment for patients with low HCV load (Genotype 1): A viral kinetic approach
journal, April 2014

  • Dahari, Harel; Cotler, Scott J.
  • Hepatology, Vol. 59, Issue 6
  • DOI: 10.1002/hep.26772

    Works referencing / citing this record:

    Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
    journal, December 2018

    • Gambato, Martina; Canini, Laetitia; Lens, Sabela
    • Liver International, Vol. 39, Issue 5
    • DOI: 10.1111/liv.14014

    Utility of viral kinetics in HCV therapy – It is not over until it is over?
    journal, February 2019

    • Sandmann, Lisa; Manns, Michael P.; Maasoumy, Benjamin
    • Liver International, Vol. 39, Issue 5
    • DOI: 10.1111/liv.14047

    Management of acute HCV infection in the era of direct-acting antiviral therapy
    journal, May 2018

    • Martinello, Marianne; Hajarizadeh, Behzad; Grebely, Jason
    • Nature Reviews Gastroenterology & Hepatology, Vol. 15, Issue 7
    • DOI: 10.1038/s41575-018-0026-5

    Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
    journal, August 2018

    • Raja, Rubesh; Baral, Subhasish; Dixit, Narendra M.
    • Immunological Reviews, Vol. 285, Issue 1
    • DOI: 10.1111/imr.12689

    Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir
    journal, July 2019

    • Huang, Chung‐Feng; Yeh, Ming‐Lun; Huang, Ching‐I
    • Journal of Gastroenterology and Hepatology, Vol. 35, Issue 1
    • DOI: 10.1111/jgh.14815

    A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics
    journal, July 2019

    • Reinharz, Vladimir; Churkin, Alexander; Lewkiewicz, Stephanie
    • Bulletin of Mathematical Biology, Vol. 81, Issue 10
    • DOI: 10.1007/s11538-019-00644-7

    Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin
    journal, July 2019

    • Lhomme, Sebastien; DebRoy, Swati; Kamar, Nassim
    • Viruses, Vol. 11, Issue 7
    • DOI: 10.3390/v11070630

    Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
    journal, July 2018


    Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil
    journal, November 2017

    • Perazzo, Hugo; Jorge, Marcelino Jose; Silva, Julio Castro
    • BMC Gastroenterology, Vol. 17, Issue 1
    • DOI: 10.1186/s12876-017-0676-8